Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | HRH1 | P35367 | 6/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | GALR2 | O43603 | 1/20 | 0.44 |
| ▸ | GALR1 | P47211 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715421 | 0.99 | HTR3A (0.53) | HTR3ASOS1CYP2D6HRH1CHRM1 | |
| SCHEMBL22726492 | 0.90 | MCHR1 (0.50) | HTR3ASOS1CYP2D6HRH1CHRM1 | |
| SCHEMBL20715696 | 0.82 | HRH1 (0.43) | HTR3ACYP2D6HRH1CHRM1KCNH2 | |
| SCHEMBL7341277 | 0.80 | HTR3A (0.75) | HTR3ACYP2D6HRH1CHRM1KCNH2 | |
| SCHEMBL23361862 | 0.80 | CSF1R (0.57) | SOS1CYP2D6 | |
| SCHEMBL4083456 | 0.80 | PPARG (0.47) | MCHR1 | |
| SCHEMBL20919806 | 0.77 | HRH1 (0.54) | HTR3ACYP2D6HRH1CHRM1KCNH2 | |
| SCHEMBL20919807 | 0.77 | HRH1 (0.54) | HTR3ACYP2D6HRH1CHRM1KCNH2 | |
| SCHEMBL22726431 | 0.75 | MCHR1 (0.55) | CYP2D6MCHR1 | |
| SCHEMBL20715427 | 0.74 | CYP2D6 (0.64) | HTR3ASOS1CYP2D6HRH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-12-03 | — | — | US | disclosed |
| WO-2019028308-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | AZI2, ATP6V1B1, GLS | HTR3A 2446/4885SOS1 4682/4885CYP2D6 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.